Journey Medical Corp (DERM) Form 10-Q — May 13, 2026
Journey Medical Corporation reported a 21% increase in total revenue to $15.961 million for the three-month period ended March 31, 2026, compared to $13.139 million in the same period of 2025. This growth is primarily driven by a significant increase in Emrosi sales, which rose from $2.070 million to $6.252 million, a 202% increase. The company's net loss decreased from $4.073 million in the first quarter of 2025 to $2.230 million in the first quarter of 2026, a 45% reduction. This improvement is attributed to a decrease in operating expenses, particularly a reduction in Emrosi launch costs.
Key figures
- Eps Beat
- 0
- Revenue
- 15961
- Total Debt
- 25000
- Debt Amount
- 25000
- Revenue Yoy
- 21
- Total Assets
- 91534
- Cash Position
- 27219
- Deal Value Usd
- 0
- Interest Rate
- 7.75
- Maturity Date
- June 27, 2028
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 27305028
Price after filing
Close on the filing date to close N calendar days later (from $5.19). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.